Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Lung cancer, non-small cell
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 813 for your search:
Start Over
Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: simcere002, simcere0802, NCT00813332
A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: SIM090801, NCT01028729
Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: sim201002, NCT01211002
Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RC08/29, NCT01320501
Maintenance Gemcitabine in the Chinese Advanced Lung Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: SHPH-11ZL113, NCT01336192
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SG 327/10, NCT01402089
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV08, NCT01665417
Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0908010555, NCT01757158
Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC
Phase: Phase IV
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRST162.05, 2012-003544-68, NCT01848613
Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IV-49, NCT01926171
Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: 5501068, NCT02088515
Validation of an Adjusted Dosing Algorithm of Carboplatin
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CARBMI, NCT02103244
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Phase: Phase IV
Type: Treatment
Status: Active
Age: 70 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABI-007-NSCL-005, NCT02151149
Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer
Phase: Phase IV
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: yl-yxb08-lcsyfa-201302, NCT02195453
Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1200.217, 2014-001077-14, NCT02208843
Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: APV-100, NCT02275702
Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IMPACT, 2012-000459-15, NCT02316327
Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CCTEBMTLA-2015, NCT02399566
High Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With EGFR 21 Exon Positive
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: AKTN-NSCLC-01, NCT02404675
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV62, NCT02103257
Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: 17 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: PH-CP010, NCT00518869
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TG4010.14/TIME, 8559, NCT01383148
Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: C-TONG 1103, ML25304, NCT01407822
Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CIKLC-201004, NCT01481259
Start Over